CTRI/2016/03/006782Recruiting未知
Efficacy and Tolerability of MetaDerm in Subjects withModerate to Severe Atopic Dermatitis - Nil
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Haus Bioceuticals Inc
- Enrollment
- 48
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Moderate to severe atopic dermatitis as determined by Physicianâ??s Global Assessment (PGA > 3.
- •Males and females, age 12 - 65 years old inclusive.
Exclusion Criteria
- •Is currently participating or has participated in another interventional clinical study at this or any other facility in the past 2 weeks.
- •Currently or has been diagnosed or treated for cancer in the past 5 years.
- •Requires any topical or systemic medications that could affect the course of their atopic dermatitis during the study period (except inhaled steroids and/or stable antihistamines for asthma or allergies).
- •Has a known hypersensitivity to any corticosteroid creams.
- •Has any active infections or has used antibiotics in the past 7 days.
- •Has any physical attributes or skin conditions that might interfere with the clear visual or instrumental assessments.(i.e. cuts, sunburn, birth marks, tattoos, extensive scarring,excessive hair growth or acne).
- •Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus rheumatoid arthritis) which could place the subject at risk or interfere with the accuracy of the study results.
- •Has used any immunosuppressant drugs or immunotherapy within the past 30 days or 5 half-lives.
- •Is an employee of the sponsor company or clinical testing site.
- •Is dependent on oral medication for any skin disease/condition or could not, in the opinion of the Investigator tolerate the restriction of discontinuing the medicine as required in this study.
- •Is currently pregnant or lactating or planning to become pregnant in the next 6 months (using double contraception for prevention).
- •Has a history of keloid formation following skin injury.
- •Is routinely taking anti-coagulant medications (i.e. Plavix,Coumadin, warfarin, heparin, etc.)
- •Any other condition or factor the Investigator or their duly assigned representative believes may affect the ability of the subject to complete the study or the interpretation of the results.
Investigators
Similar Trials
Completed
Not Applicable
To evaluate the effectiveness of MetaDerm HAT01H Cream in Atopic Dermatitis.CTRI/2017/05/008636Haus Bioceuticals Inc30
Active, not recruiting
Phase 3
Transdermal electrical stimulation in patients with retinitis pigmentosaRetinitis pigmentosaD012174JPRN-jRCT2032210094Miura Gen50
Completed
Not Applicable
A study of beneficial and adverse effects of Dermabond tissue adhesive for episcleral explants in retinal detachment surgery.retinal detachment10047060NL-OMON31281Oogziekenhuis Rotterdam75
Not yet recruiting
Phase 1
Investigating nanofat injection and conditioned medium derived from stem cells in the treatment of androgenic alopeciaHair loss.Nonscarring hair loss, unspecifiedL65.9IRCT20200127046282N34Tehran University of Medical Sciences10
Not yet recruiting
Phase 1
Investigating the safety and efficacy of injection of fat tissue cells in patients with sclerodermascleroderma.Systemic sclerosis [scleroderma]IRCT20200127046282N35Tehran University of Medical Sciences18